Herceptin

Identification

Brand Name

Herceptin

Product Description

Herceptin is a prescription HER2 receptor antagonist available in multiple countries including the United States, Canada, the EU, Italy, and Indonesia. It was first marketed in 1998. It is available in an Intravenous Injection and a Subcutaneous Injection. It contains one active ingredient: Trastuzumab. Trastuzumab is an injectable medication used to treat certain types of cancers that overexpress the HER2 protein.

Ingredients

Drug	Salt
Trastuzumab	Not Available

Pharmacology

Indications

Treatment of Breast Cancer Prescription

Treatment of HER2-Positive Early Stage Breast Cancer Prescription

Treatment of Metastatic Breast Cancer Prescription

Treatment of Metastatic Gastric Adenocarcinoma Prescription

Treatment of Metastatic Gastroesophageal Junction Adenocarcinoma Prescription

Used as adjunct in combination to treat Locally Advanced Breast Cancer (LABC) in a regimen Prescription

Used as adjunct in combination to treat metastatic HER2-positive Adenocarcinoma of the Stomach in a regimen Prescription

Used as adjunct in combination to treat metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction in a regimen Prescription

Used as adjunct in combination to treat unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach in a regimen Prescription

Used as adjunct in combination to treat unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction in a regimen Prescription

Used in combination to treat Breast Cancer in a regimen Prescription

Used in combination to treat HER2-Positive Early Stage Breast Cancer in a regimen Prescription

Used in combination to treat Hormone Receptor Positive Metastatic Breast Cancer in a regimen Prescription

Used in combination to treat Inflammatory Breast Cancer (IBC) in a regimen Prescription

Used in combination to treat Locally Advanced Breast Cancer (LABC) in a regimen Prescription

Used in combination to treat Metastatic Adenocarcinoma of the Gastroesophageal Junction in a regimen Prescription

Used in combination to treat Metastatic Adenocarcinoma of the Stomach in a regimen Prescription

Used in combination to treat Metastatic Breast Cancer in a regimen Prescription

Used in combination to treat Metastatic Gastric Adenocarcinoma in a regimen Prescription

Used in combination to treat Metastatic Gastroesophageal Junction Adenocarcinoma in a regimen Prescription

Used in combination to treat Stage I Breast Cancer in a regimen Prescription

Used in combination to treat Unresectable Breast Cancer in a regimen Prescription

Used in combination to treat Wild-type RAS Metastatic Colorectal Cancer in a regimen Prescription

Used in combination to treat unresectable RAS Wild Type Colorectal Cancer in a regimen Prescription

Products

Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	NDC Code
Injection, solution	600 mg	Subcutaneous	Roche Registration Gmbh	2016-09-08	-	EU/1/00/145/003
Injection, solution	600 mg	Subcutaneous	Roche Registration Gmbh	2016-09-08	-	EU/1/00/145/002
Injection, powder, for solution	150 mg	Intravenous	Roche Registration Gmbh	2016-09-08	-	EU/1/00/145/001
Injection, powder, for solution	440 mg		Boehringer Ingelheim	2016-10-31	2025-10-19	DKI1454500144A1
Injection	600 MG/5ML	Parenteral	Boehringer Ingelheim	2018-05-23	2023-05-23	DKI1857507343A1
Injection, powder, for solution	150 mg	Intravenous	Boehringer Ingelheim	2017-11-21	2022-11-21	DKI1657507044B1
Injection, powder, lyophilized, for solution	150 mg/7.4mL	Intravenous	Genentech, Inc.	2017-02-10	-	50242-132
Solution		Intravenous		2000-06-29	-	202M2000:1
Injection, solution	600 MG	Parenteral; Subcutaneous	Roche Registration Gmbh	2015-05-23	-	034949038
Injection, solution	600 MG/5ML	Parenteral; Subcutaneous	Roche Registration Gmbh	2014-07-08	-	034949026
Injection, powder, for solution	150 MG	Intravenous	Roche Registration Gmbh	2014-07-08	-	034949014
Powder, for solution	440 mg / vial	Intravenous	Hoffmann La Roche	1999-08-23	-	02240692
Injection	150 mg/7.4mL	Intravenous	Genentech, Inc.	1998-09-25	-	50242-134
	420 mg/20mL	Intravenous	Genentech, Inc.	1998-09-25	-	50242-333

Interactions

Drug Interaction Search

Warning: If no interactions are found between two drugs, it does not necessarily mean that no interactions exist. Always consult with a healthcare professional.

This interaction checker is limited to 5 drugs at once, available for educational and information purposes only. It is not representative of the full commercial version, which integrates into your products. Learn more

All Drug Interactions

Show all

Drug	Interaction
Integrate drug-drug interactions in your software
Abatacept	The risk or severity of neutropenia can be increased when Trastuzumab is combined with Abatacept.
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Trastuzumab.
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab.
Adalimumab	The risk or severity of neutropenia can be increased when Trastuzumab is combined with Adalimumab.
Adenovirus type 7 vaccine live	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Trastuzumab.
Aducanumab	The risk or severity of adverse effects can be increased when Trastuzumab is combined with Aducanumab.
Alclometasone	The risk or severity of neutropenia can be increased when Trastuzumab is combined with Alclometasone.
Aldesleukin	The risk or severity of neutropenia can be increased when Trastuzumab is combined with Aldesleukin.
Alefacept	The risk or severity of neutropenia can be increased when Trastuzumab is combined with Alefacept.
Alemtuzumab	The risk or severity of neutropenia can be increased when Trastuzumab is combined with Alemtuzumab.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Herceptin

Identification

Pharmacology

Interactions

Add drug to check for interactions with this medication